Literature DB >> 32068297

Rapid block of pre-mRNA splicing by chemical inhibition of analog-sensitive CRK9 in Trypanosoma brucei.

Ujwala Gosavi1, Ankita Srivastava1, Nitika Badjatia1, Arthur Günzl1.   

Abstract

Trypanosoma brucei CRK9 is an essential cyclin-dependent kinase for the parasite-specific mode of pre-mRNA processing. In trypanosomes, protein coding genes are arranged in directional arrays that are transcribed polycistronically, and individual mRNAs are generated by spliced leader trans-splicing and polyadenylation, processes that are functionally linked. Since CRK9 silencing caused a decline of mRNAs, a concomitant increase of unspliced pre-mRNAs and the disappearance of the trans-splicing Y structure intermediate, CRK9 is essential for the first step of splicing. CRK9 depletion also caused a loss of phosphorylation in RPB1, the largest subunit of RNA polymerase (pol) II. Here, we established cell lines that exclusively express analog-sensitive CRK9 (CRK9AS ). Inhibition of CRK9AS in these cells by the ATP-competitive inhibitor 1-NM-PP1 reproduced the splicing defects and proved that it is the CKR9 kinase activity that is required for pre-mRNA processing. Since defective trans-splicing was detected as early as 5 min after inhibitor addition, CRK9 presumably carries out reversible phosphorylation on the pre-mRNA processing machinery. Loss of RPB1 phosphorylation, however, took 12-24 hr. Surprisingly, RNA pol II-mediated RNA synthesis in 24 hr-treated cells was upregulated, indicating that, in contrast to other eukaryotes, RPB1 phosphorylation is not a prerequisite for transcription in trypanosomes.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  analog-sensitive kinase; chemical enzyme inhibition; cyclin-dependent kinase; pre-mRNA processing; pre-mRNA splicing

Mesh:

Substances:

Year:  2020        PMID: 32068297      PMCID: PMC7299817          DOI: 10.1111/mmi.14489

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  69 in total

1.  Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism.

Authors:  Xiaoming Tu; Ching C Wang
Journal:  Eukaryot Cell       Date:  2005-04

2.  PP1/PP2A phosphatases are required for the second step of Pre-mRNA splicing and target specific snRNP proteins.

Authors:  Yongsheng Shi; Bharat Reddy; James L Manley
Journal:  Mol Cell       Date:  2006-09-15       Impact factor: 17.970

3.  Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics.

Authors:  Stéphane Larochelle; Jasmin Batliner; Matthew J Gamble; Nora M Barboza; Brian C Kraybill; Justin D Blethrow; Kevan M Shokat; Robert P Fisher
Journal:  Nat Struct Mol Biol       Date:  2005-12-04       Impact factor: 15.369

4.  Double-stranded RNA induces mRNA degradation in Trypanosoma brucei.

Authors:  H Ngô; C Tschudi; K Gull; E Ullu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

5.  Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin.

Authors:  Tansy C Hammarton; Jade Clark; Fiona Douglas; Michael Boshart; Jeremy C Mottram
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

6.  The RNP protein, RNPS1, associates with specific isoforms of the p34cdc2-related PITSLRE protein kinase in vivo.

Authors:  P Loyer; J H Trembley; J M Lahti; V J Kidd
Journal:  J Cell Sci       Date:  1998-06       Impact factor: 5.285

7.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Authors:  David W Fry; Patricia J Harvey; Paul R Keller; William L Elliott; Maryanne Meade; Erin Trachet; Mudher Albassam; XianXian Zheng; Wilbur R Leopold; Nancy K Pryer; Peter L Toogood
Journal:  Mol Cancer Ther       Date:  2004-11       Impact factor: 6.261

8.  GT-rich promoters can drive RNA pol II transcription and deposition of H2A.Z in African trypanosomes.

Authors:  Carolin Wedel; Konrad U Förstner; Ramona Derr; T Nicolai Siegel
Journal:  EMBO J       Date:  2017-07-12       Impact factor: 11.598

9.  An essential domain of an early-diverged RNA polymerase II functions to accurately decode a primitive chromatin landscape.

Authors:  Anish Das; Mahrukh Banday; Michael A Fisher; Yun-Juan Chang; Jeffrey Rosenfeld; Vivian Bellofatto
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

10.  The phosphoproteome of bloodstream form Trypanosoma brucei, causative agent of African sleeping sickness.

Authors:  Isabelle R E Nett; David M A Martin; Diego Miranda-Saavedra; Douglas Lamont; Jonathan D Barber; Angela Mehlert; Michael A J Ferguson
Journal:  Mol Cell Proteomics       Date:  2009-04-04       Impact factor: 7.381

View more
  4 in total

1.  Bromodomain factor 5 is an essential regulator of transcription in Leishmania.

Authors:  Nathaniel G Jones; Vincent Geoghegan; Gareth Moore; Juliana B T Carnielli; Katherine Newling; Félix Calderón; Raquel Gabarró; Julio Martín; Rab K Prinjha; Inmaculada Rioja; Anthony J Wilkinson; Jeremy C Mottram
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

2.  Nuclear mRNA maturation and mRNA export control: from trypanosomes to opisthokonts.

Authors:  Susanne Kramer
Journal:  Parasitology       Date:  2021-01-19       Impact factor: 3.234

3.  Drug Target Validation of the Protein Kinase AEK1, Essential for Proliferation, Host Cell Invasion, and Intracellular Replication of the Human Pathogen Trypanosoma cruzi.

Authors:  Miguel A Chiurillo; Bryan C Jensen; Roberto Docampo
Journal:  Microbiol Spectr       Date:  2021-09-29

4.  A distinct complex of PRP19-related and trypanosomatid-specific proteins is required for pre-mRNA splicing in trypanosomes.

Authors:  Ankita Srivastava; Daniela L Ambrósio; Monika Tasak; Ujwala Gosavi; Arthur Günzl
Journal:  Nucleic Acids Res       Date:  2021-12-16       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.